• Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker used to treat benign hyperplasia of prostate with, lower urinary tract symptoms.

Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker.
Naftopidil is prescribed in Japan for the treatment of benign prostatic hyperplasia (BPH) and benign prostatic obstruction, associated with lower urinary tract symptoms (LUTS), hypertension, cardiac valve disease, and distal ureteral stones.

Further large-scale, randomized, placebo-controlled studies need to be done to see if the naftopidil efficacy and safety data that is applicable to Japanese can be extended to white, black and Hispanic men having LUTS/BPH in western countries. 

• Naftopidil is contraindicated in patients with allergies to the drug.

• The recommended dose for the drug is 50 to 75 mg per day for 4 weeks.

• Naftopidil tablets should be taken in three divided doses by mouth.

• Check with your doctor if you are pregnant or nursing, have salt imbalance or orthostatic hypotension before taking the medication

• The side effects are very few and usually mild with dizziness and low blood pressure.

• Caution should be taken in patients with diabetes.

• Naftopidil may interact with indapamide and its analogs

• Naftopidil should be stored at room temperature